Return to content in this issue

 

First line versus second line use of reslizumab in severe uncontrolled asthma

Pérez de Llano LA1*, Cosío BG2*, Lobato Astiárraga I3, Soto Campos G4, Tejedor Alonso MA5, Malanda NM6, Padilla Galo A7, Urrutia Landa I8, Michel de la Rosa FJ9, García-Moguel I10, on behalf of the Reslizumab real-life Spanish group**.

1Pneumology Service, Hospital Lucus Augusti, Lugo, Spain
2Pneumology Service, Hospital Universitario Son Espases-IdISBa-Ciberes, Palma de Mallorca, Spain
3Pneumology Service, Complejo Asistencial de Ávila, Ávila, Spain
4Pneumology and Allergy Unit, University Hospital of Jerez, Jerez de la Frontera, Cádiz, Spain
5Allergy Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain
6Pneumology Service, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
7Pneumology Service, Hospital Costa del Sol, Marbella, Málaga, Spain
8Respiratory Department, Galdakao Hospital, Galdakao, Bizkaia, Spain
9Pneumology Service, Hospital Universitario Donostia, San Sebastian, Spain
10Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain
* Co-Primary authors
** The full list of the Reslizumab real-life Spanish group is included in the appendix.

J Investig Allergol Clin Immunol 2023; Vol. 33(3)
doi: 10.18176/jiaci.0839

Key words: Eosinophilic asthma, Reslizumab, Asthma control, Monoclonal antibodies